abstract |
The present invention relates to physiological and / or pathophysiological conditions caused, mediated and / or propagated by compounds according to formula (I) and / or increased lysophosphatidic acid levels and / or activation of autotaxin, as autotaxin inhibitors, In particular it relates to the use of said compounds for the treatment and / or prophylaxis of different cancers. |